MAX BioPharma and Revilico Announce Collaboration on Target Identification and Mechanistic Studies for Oxysterol Drug Candidates

August 6, 2025 8:00 AM

Today MAX BioPharma, Inc. (www.maxbiopharma.com) and Revilico, Inc. (www.revilico.bio) announced their collaboration in studying the mechanisms of action, performing lead optimization, and identifying the molecular targets of MAX BioPharma's oxysterol-based drug candidates using a state-of-the-art, AI-enabled, end-to-end drug discovery platform developed by Revilico. "We are extremely excited about forming this important collaboration between...

Read more

Inside Information: Faron to Present Updated BEXMAB Data in Frontline HR-MDS to FDA; Complete Remission Rate Substantially Increased to 43%

August 6, 2025 2:20 AM

Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company focused on tackling cancers through novel immunological pathways, today announced an increase in the complete remission (CR) rate in patients with frontline or treatment-naïve high-risk myelodysplastic syndrome (HR-MDS), based on updated efficacy data from its Phase 1/2 BEXMAB trial.According to the investigator-assessed response using IWG 2006...

Read more

IGC Pharma Reports IGC-M3's In Vitro Efficacy Against Alzheimer's - Targeting key Drivers of Disease Progression

August 5, 2025 9:00 AM

IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage pharmaceutical company leveraging AI to develop innovative treatments for Alzheimer's and metabolic disorders, today announced encouraging preclinical data on its investigational molecule "IGC-M3". The invitro results demonstrates that IGC-M3 may offer disease-modifying potential by targeting multiple biological mechanisms central to Alzheimer's pathology, including...

Read more

Biovica announces outcome of rights issue

August 5, 2025 8:15 AM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - The Board of Directors of Biovica International AB (publ) ("Biovica" or the "Company") announced on 11 June 2025, subject to subsequent approval by an extraordinary general meeting, that the Board of Directors had resolved to carry out a new issue of A-shares and B-shares of approximately SEK 80.1 million with preferential rights for the Company's shareholders (the "Rights Issue")....

Read more

Nancy Davis, Visionary Philanthropist and Founder of Race to Erase MS and Cure Addiction Now Appointed to the Tharimmune Board of Directors

August 5, 2025 8:00 AM

Tharimmune, Inc. (NASDAQ:THAR), ("Tharimmune" or the "Company), a clinical-stage biotechnology company dedicated to developing innovative therapeutic candidates for inflammation, immunology, and critical unmet medical needs, today proudly announced the appointment of Nancy Davis, a globally recognized philanthropist, tenacious advocate, and the visionary founder of the renowned Race to Erase MS and Cure Addiction Now foundations, to its Board of...

Read more

ClearPoint Neuro Announces Progression of Key Partner Milestones throughout the Global Biologics and Drug Delivery Portfolio

August 4, 2025 4:05 PM

ClearPoint Neuro, Inc. (NASDAQ:CLPT) ("Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced multiple key milestones demonstrating the progression of the Company's Biologics and Drug Delivery Portfolio including first commercial infusions in the United States, additional partners accepted for expedited review, creation of cell and gene infusion ICD-10 codes, and...

Read more

enVVeno Medical Participates in a New Virtual Investor "What This Means" Segment to Discuss How President Trump's Recent CVI Diagnosis May Impact the Company

August 4, 2025 9:05 AM

enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno Medical" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that it participated in a Virtual Investor "What This Means" segment entitled, "enVVeno Medical - Making Veins Work Again - How President Trump's CVI Diagnosis is Raising Awareness." Rob Berman, CEO and Dr. Marc Glickman, CMO of enVVeno Medical discussed the...

Read more

Tharimmune Issues Comprehensive Corporate Update including Lead TH104 as Critical National Security Solution Against Weaponized Fentanyl and TH023 Poised to Revolutionize Oral Antibody Delivery

August 4, 2025 8:00 AM

Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company dedicated to developing innovative therapeutic candidates for inflammation, immunology, and critical unmet medical needs, today issued a comprehensive corporate update highlighting significant advancements across its pipeline. The update underscores the rapid progression of TH104 as a lead asset addressing critical national security risks posed...

Read more

CytoNiche Launches 3D FloTrix Experience Center in Singapore to Advance Affordable Stem Cell Therapies

August 1, 2025 9:45 AM

CytoNiche Biotech, a leader in 3D cell mass production technology, has opened its 3D FloTrix™ Experience Center in Singapore. This milestone marks a key step in the company's global expansion, showcasing the technology behind China's first approved stem cell therapy, with costs estimated by the company to be a fraction of comparable Western therapies.The high cost of stem cell therapies remains a global barrier. For example, stem cell therapy...

Read more

enVVeno Medical Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 1, 2025 8:00 AM

enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today reported financial results for the second quarter 2025."As the recent headlines around CVI confirmed, CVI is a pervasive and a progressive disease that is especially debilitating once it becomes severe. Our participation in several of the recent national news stories about CVI...

Read more

Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell Lymphoma

July 30, 2025 9:00 AM

Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its collaboration partner, PeriNess Ltd. ("PeriNess"), has entered into a Clinical Study Agreement (the "Agreement") to support an exploratory clinical study of DNase I in combination with anti-CD19 CAR T cells in patients with...

Read more

IBN Initiates Coverage of AI Maverick Intel Inc.

July 30, 2025 7:00 AM

AI Maverick Intel Inc. (OTC:BINP), a technology-forward company focused on transforming how businesses acquire and engage customers through artificial intelligence, has selected IBN, a multifaceted financial news and publishing company serving private and public entities, to spearhead its corporate communications efforts.AI Maverick Intel delivers human-like, AI-powered prospecting through its proprietary platform, enabling intelligent...

Read more

Faron Announces Acceptance of Bexmarilimab Data for Oral Presentation at ESMO 2025

July 30, 2025 2:50 AM

Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company developing novel immunotherapies, announces that new clinical and translational data from the Phase I/II BEXMAB study evaluating bexmarilimab in combination with azacitidine in higher-risk myelodysplastic syndromes (HR-MDS) will be presented as a part of a Mini Oral Abstract Session at the 2025 European Society for Medical Oncology (ESMO)...

Read more

Diorasis Therapeutics and Northway Biotech Announce Partnership for the Development and Manufacturing of AAV Gene Therapy for Glaucoma

July 29, 2025 8:30 AM

Diorasis Therapeutics ("DTx"), a preclinical-stage biotechnology company developing gene therapies for ophthalmic diseases, has entered into a strategic partnership with Northway Biotech ("NBT"), a contract development and manufacturing organization (CDMO), to establish a scalable cGMP production process for DTx's lead AAV-based gene therapy candidate for open angle glaucoma.As part of the collaboration, Northway Biotech will leverage its 20...

Read more

eXoZymes Details Biomanufacturing Breakthrough: 4 Grams of NCT with Over 99% Purity

July 29, 2025 7:57 AM

Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - together with its spinout NCTx, announced additional numbers from their biomanufacturing breakthrough - achieving a purity higher than 99% in the initial lab scale validation that produced 4 grams of NCT.Co-founder and VP of Research, Dr. Tyler Korman,...

Read more

Biolog Enters the European Diagnostic Market, Bringing 45 Years of Anaerobic Culture Excellence

July 29, 2025 4:00 AM

Biolog, a leading provider of microbial identification and phenotypic characterization tools and services, announced today that both its anaerobic media and anaerobic chambers have received CE marking, clearing the way for broader international use. The media and chambers were part of Biolog's acquisition of Anaerobe Systems earlier this year with the objective of bringing class-leading tools for microbiology to the rapidly growing clinical,...

Read more

Lobe Sciences Announces $341,425 CAD Private Placement for General Corporate Purposes

July 29, 2025 12:10 AM

Lobe Sciences Ltd. ("Lobe Sciences" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a biopharmaceutical company focused on developing therapeutics for rare and underserved diseases, is pleased to announce a non-brokered private placement (the "Offering") of up to 8,535,625 common share of the Company (each, a "Share") at a price of $0.04 per Share for gross proceeds of up to $341,425 CAD.The net proceeds of the Offering will be used for...

Read more

Lobe Sciences Ltd. Engages ArcStone Securities for Strategic Capital Markets Advisory

July 29, 2025 12:08 AM

Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a biopharmaceutical company focused on developing therapeutics for rare and underserved diseases, today announced its formal engagement with ArcStone Securities and Investments Corp. ("ArcStone"), a capital markets advisory firm.Under the terms of the agreement, ArcStone will provide Lobe Sciences with comprehensive advisory services, including capital markets planning, institutional...

Read more

Renovaro Secures Key AI Patents, Strengthening Market Position in $20B Biomedical AI Sector

July 28, 2025 10:38 AM

Renovaro (NASDAQ:RENB), a precision-medicine technology company, today announced multiple U.S. patent allowances that significantly strengthen its competitive position in biomedical artificial intelligence. The new patents, including U.S. Application No. 18/058,732 for unbiased drug discovery predictions, expand Renovaro's growing IP portfolio anchored by foundational patents U.S. No. 11,379,757 and recently awarded Application No....

Read more

Taran Therapeutics Reports Publication from PREACH-M Trial for Chronic Myelomonocytic Leukemia in Current Edition of the European Medical Journal

July 28, 2025 8:00 AM

Taran Therapeutics ("Taran") a privately held company focused on hematology/oncology, announced the publication of a paper entitled ‘Durable Responses to Lenzilumab: Azacitidine Combination Therapy in High Risk Proliferative Chronic Myelomonocytic Leukaemia with Suppression of CBL and RAS Mutant Subclones' in the July 2025 edition of the European Medical Journal, Hematology edition.The paper reports on the PREACH-M study assessment to date with...

Read more